← All trials
NCT02608437
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2015
- Primary completion
- Oct 1, 2016
- Completion date
- Oct 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 19
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Italian Network for Tumor BiotherapyLead sponsor
- University of SienaOverall official - principal investigator
- Astex Pharmaceuticals, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.